Boardroom Alpha
Boardroom Alpha
DGX · Current Report (Form 8-K) · Filed May 21, 2026

Quest Diagnostics Inc — Current Report (Form 8-K)

Form
8-K
Filed
May 21, 2026
Period
May 20, 2026
Ticker
DGX
Accession
0001022079-26-000052
Boardroom Alpha · Filing insights

Quest Diagnostics stockholders elected directors for 2027 terms, approved executive compensation, ratified PwC, and rejected an independent board chair proposal.

About Quest Diagnostics Inc
Market cap
$26.8B
1Y TSR
+36.5%
3Y TSR
+23.6%
Board grade
C+
Sector
Healthcare
CEO
J E Davis
Last annual meeting: May 20, 2026 · View full Quest Diagnostics Inc profile →
dgx-20260520

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): May 20, 2026
Quest Diagnostics Incorporated
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or other jurisdiction of incorporation)
001-1221516-1387862
(Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive
Secaucus, NJ07094
(Address of principal executive offices)(Zip Code)
(973)520-2700
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 Par ValueDGXNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

1


Item 5.07 Submission of Matters to a Vote of Security Holders

(a)           The following is a summary of the voting results for each matter presented to the stockholders at the 2026 Annual Meeting of Stockholders which was held on May 20, 2026.

(b)           The following nominees for the office of director were elected for terms expiring at the 2027 Annual Meeting of Stockholders, by the following votes:
FOR
AGAINST
ABSTAIN
NON-VOTES
Robert B. Carter
93,821,069
205,166
173,510
9,135,906
James E. Davis
88,799,800
5,237,756
162,189
9,135,906
Luis A. Diaz, Jr., M.D.
93,909,369
110,114
180,262
9,135,906
Tracey C. Doi
93,649,938
393,268
156,539
9,135,906
Vicky B. Gregg
83,814,387
10,232,574
152,784
9,135,906
Wright L. Lassiter, III
93,802,306
223,154
174,285
9,135,906
Timothy L. Main
88,302,767
5,614,920
282,058
9,135,906
Denise M. Morrison
89,808,461
4,176,407
214,877
9,135,906
Gary M. Pfeiffer
86,302,153
7,716,970
180,622
9,135,906
Timothy M. Ring
81,917,543
11,994,424
287,778
9,135,906
Timothy C. Wentworth
93,427,490
597,095
175,160
9,135,906

The advisory resolution to approve the executive officer compensation disclosed in the Company’s 2026 Proxy Statement was approved by the following votes:

FOR
AGAINST
ABSTAIN
NON-VOTES
86,869,738
7,152,448
177,559
9,135,906

The ratification of the appointment of PricewaterhouseCoopers as the Company’s independent registered public accounting firm for 2026 was approved by the following votes:

FOR
AGAINST
ABSTAIN
97,340,034
5,809,995
185,622


The stockholder proposal regarding an independent board chairman was not approved by the following votes:

FORAGAINSTABSTAINNON-VOTES
23,999,63669,792,819407,2909,135,906



2


Signature
    
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

May 21, 2026

QUEST DIAGNOSTICS INCORPORATED
By:/s/ Sean D. Mersten
Sean D. Mersten
Vice President and Corporate Secretary



3
From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Quest Diagnostics Inc (DGX)

Reference

Frequently asked questions

When did Quest Diagnostics Inc file this 8-K?
Quest Diagnostics Inc (DGX) filed this Current Report (Form 8-K) with the SEC on May 21, 2026. The accession number assigned by EDGAR is 0001022079-26-000052.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Quest Diagnostics stockholders elected directors for 2027 terms, approved executive compensation, ratified PwC, and rejected an independent board chair proposal. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Quest Diagnostics Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Quest Diagnostics Inc has filed under CIK 1022079, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer